title: Comparison of apoptosis detection markers combined with macrophage immunostaining to study phagocytosis of apoptotic cells in situ.
abstract: Efficient phagocytosis of cells undergoing apoptosis by macrophages is important to prevent immunological responses and development of chronic inflammatory disorders such as systemic lupus erythematosus, cystic fibrosis and atherosclerosis. To study phagocytosis of apoptotic cells (AC) by macrophages in tissue, we validated different apoptosis markers (DNA fragmentation, caspase-3 activation and cleavage of its substrate poly(ADP-ribose)polymerase-1) in combination with macrophage immunostaining. Human tonsils were used as a model because they show a high apoptosis frequency under physiological conditions as well as efficient phagocytosis of AC by macrophages. On the other hand, advanced human atherosclerotic plaques were examined since plaques show severely impaired phagocytosis of AC. Our results demonstrate that the presence of non-phagocytized terminal deoxynucleotidyl transferase end labelling (TUNEL)-positive AC represents a suitable marker of poor phagocytosis by macrophages in situ. Other markers for apoptosis, such as cleavage of caspase-3 or PARP-1, should not be used to assess phagocytosis efficiency, because activation of the caspase cascade and cleavage of their substrates can occur in AC when they have not yet been phagocytized by macrophages.
authors.affiliation: Division of Pharmacology, University of Antwerp, Wilrijk, Belgium.
authors.forename: Dorien M
authors.initials: DM
authors.lastname: Schrijvers
authors.forename: Guido R Y
authors.initials: GR
authors.lastname: De Meyer
authors.forename: Mark M
authors.initials: MM
authors.lastname: Kockx
authors.forename: Arnold G
authors.initials: AG
authors.lastname: Herman
authors.forename: Wim
authors.initials: W
authors.lastname: Martinet
references.citation: Hepatology. 1995 May;21(5):1465-8
references.pmid: 7737654
references.citation: Am J Pathol. 1998 Apr;152(4):885-8
references.pmid: 9546348
references.citation: Arterioscler Thromb Vasc Biol. 2005 Jun;25(6):1256-61
references.pmid: 15831805
references.citation: Cell Death Differ. 2003 Jan;10(1):108-16
references.pmid: 12655299
references.citation: FEBS Lett. 2000 Jan 7;465(1):47-52
references.pmid: 10620704
references.citation: J Clin Invest. 2001 Oct;108(7):957-62
references.pmid: 11581295
references.citation: Eur J Immunol. 1996 Jun;26(6):1211-6
references.pmid: 8647194
references.citation: Immunol Cell Biol. 2003 Aug;81(4):289-96
references.pmid: 12848850
references.citation: Arthritis Rheum. 2002 Jan;46(1):191-201
references.pmid: 11817590
references.citation: Arthritis Rheum. 2003 Oct;48(10):2888-97
references.pmid: 14558095
references.citation: J Clin Invest. 2002 Mar;109(5):661-70
references.pmid: 11877474
references.citation: Neurosci Lett. 1996 Aug 2;213(2):111-4
references.pmid: 8858621
references.citation: Neurosci Lett. 1997 Jul 11;230(1):1-4
references.pmid: 9259449
references.citation: Cancer Metastasis Rev. 1992 Sep;11(2):95-103
references.pmid: 1394797
references.citation: Ann Rheum Dis. 2004 Jul;63(7):774-84
references.pmid: 15194571
references.citation: Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8485-9
references.pmid: 1924307
references.citation: Cell. 2003 Jun 13;113(6):717-30
references.pmid: 12809603
references.citation: J Immunol Methods. 2004 Apr;287(1-2):101-8
references.pmid: 15099759
references.citation: Ann Rheum Dis. 2005 Feb;64(2):342-3; author reply 343-4
references.pmid: 15647451
references.citation: Arthritis Rheum. 2004 Jun;50(6):1873-83
references.pmid: 15188364
references.citation: Genes Dev. 1998 Mar 15;12(6):806-19
references.pmid: 9512515
references.citation: Arterioscler Thromb Vasc Biol. 1999 Oct;19(10):2524-34
references.pmid: 10521383